Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr 28:348:g2688.
doi: 10.1136/bmj.g2688.

Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis

Alexandra N Nowbar  1 , Michael Mielewczik, Maria Karavassilis, Hakim-Moulay Dehbi, Matthew J Shun-Shin, Siana Jones, James P Howard, Graham D Cole, Darrel P Francis; DAMASCENE writing group
Affiliations
Review

Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis

Alexandra N Nowbar et al. BMJ. .

Abstract

Objective: To investigate whether discrepancies in trials of use of bone marrow stem cells in patients with heart disease account for the variation in reported effect size in improvement of left ventricular function.

Design: Identification and counting of factual discrepancies in trial reports, and sample size weighted regression against therapeutic effect size. Meta-analysis of trials that provided sufficient information.

Data sources: PubMed and Embase from inception to April 2013.

Eligibility for selecting studies: Randomised controlled trials evaluating the effect of autologous bone marrow stem cells for heart disease on mean left ventricular ejection fraction.

Results: There were over 600 discrepancies in 133 reports from 49 trials. There was a significant association between the number of discrepancies and the reported increment in EF with bone marrow stem cell therapy (Spearman's r=0.4, P=0.005). Trials with no discrepancies were a small minority (five trials) and showed a mean EF effect size of -0.4%. The 24 trials with 1-10 discrepancies showed a mean effect size of 2.1%. The 12 with 11-20 discrepancies showed a mean effect of size 3.0%. The three with 21-30 discrepancies showed a mean effect size of 5.7%. The high discrepancy group, comprising five trials with over 30 discrepancies each, showed a mean effect size of 7.7%.

Conclusions: Avoiding discrepancies is difficult but is important because discrepancy count is related to effect size. The mechanism is unknown but should be explored in the design of future trials because in the five trials without discrepancies the effect of bone marrow stem cell therapy on ejection fraction is zero.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Figures

None
Fig 1 Identification of randomised controlled trials of autologous bone marrow stem cells for heart disease (EF=ejection fraction)
None
Fig 2 Correlation between number of discrepancies in trial’s reports and ejection fraction (EF) effect size. Dot area is proportional to trial’s sample size (Spearman’s r=0.4, P=0.005)
None
Fig 3 Mean ejection fraction (EF) effect size by number of discrepancies in trial’s reports. Error bars here show only SE of mean effect size weighted for sample size across trials in each category. Formal meta-analytic confidence intervals, which fully integrate sample size and uncertainty within each trial, are available only for subset of trials (see appendix 10)
See this image and copyright information in PMC

Comment in

References

    1. Jeevanantham V, Butler M, Saad A, Abdel-Latif A, Zuba-Surma EK, Dawn B. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation 2012;126:551-68. - PMC - PubMed
    1. Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organization and United Nations. Int J Cardiol 2012;168:934-45. - PMC - PubMed
    1. Zimmet H, Porapakkham P, Porapakkham P, Sata Y, Haas SJ, Itescu S, et al. Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Eur J Heart Fail 2012;14:91-105. - PubMed
    1. Clifford DM, Fisher SA, Brunskill SJ, Doree C, Mathur A, Watt S, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Sys Rev 2012;2:CD006536. - PubMed
    1. Francis DP, Mielewczik M, Zargaran D, Cole GD. Autologous stem cell therapy in heart disease: silent discrepancies and scientific and editorial responses. Int J Cardiol 2013;168:3381-403. - PubMed

MeSH terms